Choose the right cancer treatment: PrIMe Multi-gene assay provides a comprehensive picture of the tumor biology. This helps physicians and patients choose a personalized cancer treatment.
This way the physician has a clear indication of which treatments will benefit the patient and which not, including immunotherapy.
Continuous support to the doctor and the patient from our experienced team.
The procedure for PrIMe test or any other test at Genekor Medical S.A. does not end with the results report.
Our experienced customer service and scientific consulting teams work with the physician and patient throughout the process. Both teams guide the patient throughout the examination process and provide information on new data and recommended treatments on a case-by-case basis, creating a strong support system for both.
The evolved version of the assay selected for the MATCH clinical study: The PrIMe method is the evolution of a widely validated study selected by the National Cancer Institute in the United States. It was used as an analysis of choice for the stratification of more than 3,000 patients participating in the clinical trial (Molecular Analysis for Therapy Choice) to assign targeted individualized treatments.
MATCH is the first multicenter clinical study in which the targeted therapeutic approach is based on the analysis of molecular pathways of the tumor, regardless of the organ of origin.
State of the art, sensitive and reliable technology: The sequencing is carried out using the Ion Torrent Next Generation Sequensing platfrom “Ion GeneStudio™ S5 PrIME System”. This is a state of the art technology, which has demonstrated high reproducibility, sensitivity and specificity. Moreover, this Technology has been adopted by the leading cancer institutions worldwide, including National Cancer Institute.